Scopulariopsis fungal endophthalmitis after cataract surgery requiring enucleation Authors: Sunny Qin, Rajiv E Shah, Tal J Rubinstein, Preeti Parekh, Kristen S Godwin Published: 2026 ABSTRACT AbstractPurposeTo report a rare case of post-cataract surgery related endophthalmitis caused by Scopulariopsis species and describe the therapeutic challenges associated with this multidrug-resistant opportunistic fungal pathogen.Case descriptionA 74-year-old immunocompromised female developed chronic endophthalmitis three months after cataract surgery in Africa. Vitreous culture revealed polymicrobial infection with Scopulariopsis species demonstrating resistance to azole antifungals but susceptibility to micafungin. Despite aggressive treatment including pars plana vitrectomy, systemic micafungin, and intravitreal amphotericin B injections, the patient developed phthisis bulbi and persistent pain, ultimately requiring enucleation. Histopathological examination revealed persistent fungal hyphae despite three months of intensive antifungal therapy.ConclusionScopulariopsis endophthalmitis represents an extremely rare but devastating infection with inherent therapeutic resistance. Even with aggressive multimodal antifungal therapy guided by susceptibility testing, complete eradication may not be achievable, highlighting the importance of early recognition and realistic prognostic counseling for these challenging infections.Keywords: Scopulariopsis, Fungal endophthalmitis, Postoperative endophthalmitis, Antifungal resistance, Exogenous endophthalmitis Introduction Endophthalmitis is a rare but devastating complication of intraocular surgery that can result in severe visual impairment, blindness, or loss of the eye. While bacterial pathogens account for the majority of the cases, fungal endophthalmitis represents a particularly challenging subset due to its often delayed presentation, diagnostic difficulties, and limited therapeutic options. In the United States, the incidence of fungal endophthalmitis has been reported to be 0.002% to 0.005% [1]. Studies have shown considerable geographic variation, with higher rates reported in tropical regions and developing countries, where fungal pathogens are more prevalent in the environment [2,3]. Aspergillus is the most common causative fungal organism (56-74% of the cases), followed by Candida (11-19% of the cases) [4,5]. Scopulariopsis is a fungal genus that includes both hyaline and dematiaceous species, commonly isolated from soil, air, plant debris, paper, and moist environments [6]. Scopulariopsis can present as an opportunistic pathogen, mainly causing superficial tissue infections, such as nondermatophytic onchomycoses [6,7]. When ocular infections have been reported, it has mainly been isolated from post-traumatic or postoperative keratitis, postoperative endophthalmitis, and intravenous drug use-associated endophthalmitis [[8], [9], [10], [11], [12]]. What makes Scopulariopsis particularly challenging in the clinical setting is its inherent resistance to the standard antifungal agents, including voriconazole, itraconazole, and posaconazole, as well as amphotericin B [6]. Therefore, the optimal therapeutic treatment for ocular infections remains poorly defined due to the rarity of these cases. In addition to the difficulty in treatment options, the delayed presentation of fungal endophthalmitis, which may occur weeks to months after surgery, can further complicate diagnosis and management. We present a case of delayed presentation of chronic fungal endophthalmitis secondary to a Scopulariopsis infection following cataract surgery. This case will highlight the diagnostic challenges of this species, antifungal resistance patterns, and treatment complexities associated with this rare, but sight-threatening, infection. Case presentation Our patient was a 74-year-old female with a past medical history of hepatocellular carcinoma and Hepatitis C on immunotherapy who presented to the emergency department with a three-day history of right eye pain and vision loss. Her past ocular history was significant for right eye phacoemulsification with posterior chamber intraocular lens implantation three months prior in Cameroon, Africa. On review of her past medical records, her initial surgery was complicated by a postoperative hyphema that required an anterior chamber washout. Her reported visual acuity on her last follow up in Africa was hand motion. On presentation to our hospital, her visual acuity was light perception in the right eye. Anterior segment examination revealed a near-total epithelial defect, mixed fibrin and dehemoglobinized blood products and a <1 mm hypopyon in the anterior chamber (Fig. 1). There was no view on posterior examination and so B-scan ultrasonography was performed that showed a dense vitritis. A vitreous tap was performed and intravitreal injections of ceftazidime and vancomycin were administered. The patient was scheduled to return for follow up the following day. Slit lamp photograph of right eye at presentation. Her examination one day later revealed a stable exam but worsening pain. Due to lack of improvement of her clinical picture, the decision was made to perform an emergency vitrectomy. She subsequently underwent a 23-gauge pars plana vitrectomy with 5000 centistoke silicone oil placement and repeat intravitreal injections of vancomycin (1.0 mg/0.1 mL) and ceftazidime (2.25 mg/0.1 mL). Of note, intraoperatively it was discovered that the scleral tunnel wound from her previous cataract surgery was dehisced and there was uveal prolapse. The wound was repaired with 9-0 nylon sutures, and the prolapsed uveal tissue was repositioned until a watertight closure was achieved. Repeat vitreous cultures were collected intraoperatively and were positive for Scopulariopsis species along with 3+ polymorphonuclear leukocytes and 2+ gram-positive cocci in clusters. This confirmed a polymicrobial intraocular infection with both bacterial and fungal components. Initial treatment included oral fluconazole, topical moxifloxacin, topical voriconazole, and topical amphotericin B. An infectious disease consultation was also obtained, and systemic antifungal therapy was escalated to oral voriconazole (200 mg twice daily). Antifungal susceptibility testing (AFST) was performed by broth microdilution per the Clinical and Laboratory Standards Institute (CLSI) M38 reference method, with quality control and incubation conditions in accordance with the M38 standard. As clinical breakpoints have not been established for Scopulariopsis species, results were reported as raw minimum inhibitory concentration (MIC) values without categorical interpretation. The isolate demonstrated elevated MICs to amphotericin B (4 μg/mL), fluconazole (>64 μg/mL), itraconazole (>16 μg/mL), posaconazole (>16 μg/mL), and voriconazole (>16 μg/mL), with the lowest MIC observed for micafungin (0.125 μg/mL). Shortly after initiation of voriconazole, the patient developed severe hyponatremia (serum sodium 117 mmol/L) and transaminitis, requiring hospitalization and discontinuation of the agent. Given this adverse drug reaction together with the demonstrated azole resistance and the favorable micafungin MIC, systemic therapy was transitioned to high-dose intravenous micafungin at 200 mg daily, with the increased dose intended to maximize ocular drug concentrations despite the agent's known suboptimal vitreous penetration. The patient's clinical course was complicated by a recurrent hypopyon and new pain that developed on postoperative day 19. This prompted our team to perform a repeat vitreous tap and intravitreal injection of amphotericin B. Despite aggressive treatment with topical voriconazole, topical amphotericin B and intravenous micafungin, the patient continued to have a persistent hypopyon and severe pain. She received a total of three intravitreal amphotericin B injections at 1.5-week intervals and completed six weeks of intravenous micafungin therapy. After three months of intensive treatment, the infection became clinically quiescent, however, the patient's visual acuity remained at light perception and she developed phthisis bulbi with persistent ocular pain. Extensive discussions about the goals of care were had with the patient and her family, and ultimately, she underwent enucleation. During enucleation, scleral necrosis was noted inferiorly around the inferior rectus muscle with dense fibrinous scar tissue. Following eye removal, an 18 mm cadaveric scleral wrapped silicone sphere implant was inserted. Orbital biopsies inferiorly noted chronic inflammation without fungal elements. Histopathological examination of the globe, however, showed persistent fungal hyphae on Grocott's Methenamine Silver (GMS) staining at the site of scleral necrosis (Fig. 2A–C). Histopathology of the enucleated globe at the site of scleral necrosis. (A) Low-power view demonstrating ulceration with stromal acute inflammation, histiocytic infiltration, and necrosis at the uveal-scleral junction (hematoxylin and eosin; original magnification 40×). (B) Higher-power view showing thin, elongated, hyaline septate fungal hyphae (arrow) embedded within the dense collagenous sclera (hematoxylin and eosin; original magnification 100×). (C) Grocott's Methenamine Silver (GMS) stain highlighting branching, septate fungal hyphae (arrow), confirming the morphology of a hyaline septate mold consistent with the cultured isolate of Scopulariopsis sp. (original magnification 200×). Due to continued fungal elements found in the sclera, she was restarted on micafungin for 2 more weeks. Post-operative retrobulbar injections of amphotericin were contemplated, but due to routine and uneventful post-operative course, they were not performed. At 7 months follow up, she was pain free without any sign of orbital inflammation, and she was wearing an ocular prosthesis without complications. Discussion Scopulariopsis endophthalmitis represents an exceedingly rare manifestation of ocular infection by this opportunistic mold. A review of the literature reveals only sporadic case reports of Scopulariopsis ocular infections, with most cases involving keratitis. Malecha reported successful treatment of Scopulariopsis brevicaulis keratitis with topical natamycin, while another case described successful management of S. brevicaulis keratitis using topical amphotericin B and chloramphenicol without surgical debridement [8,12]. Post-operative keratitis has also been reported, with one case involving interface infection following Descemet's stripping automated endothelial keratoplasty with a contaminated graft, and one case of keratitis following Lasik [13,14]. Most notably, Aydin et al. reported a case of post-operative Scopulariopsis endophthalmitis that was successfully treated with topical and intravenous voriconazole and caspofungin [11]. The rarity of Scopulariopsis endophthalmitis makes our case particularly significant, as it adds to the limited body of literature describing the clinical presentation, treatment challenges, and outcomes associated with intraocular infection by this resistant organism. The presence of this patient's dehisced scleral tunnel wound with uveal prolapse likely provided the portal of entry for this fungus. The antifungal resistance pattern demonstrated by our patient's fungal isolate is characteristic of the Scopulariopsis species. Extensive in vitro studies have consistently shown that Scopulariopsis exhibits remarkably high resistance to practically all current antifungal agents [6,15]. Amphotericin B effectiveness is estimated at only 40% of cases, resulting in high mortality rates and frequent treatment failures [6,15]. Our isolate's resistance to fluconazole and voriconazole, but susceptibility to micafungin, was in accordance with the results of these in vitro studies [6,15,16]. Although echinocandins are not generally recommended as first-line therapy for fungal endophthalmitis due to their large molecular weight, high protein binding, and consequently poor vitreous penetration, the multidrug-resistant profile of our isolate combined with intolerance of voriconazole left few viable therapeutic alternatives [17,18]. Available pharmacokinetic data indicate that intravenous echinocandins may achieve adequate concentrations in the cornea, iris, retina, and choroid but only subtherapeutic levels in the aqueous and vitreous [19]. On this basis, Mochizuki et al. recommended that intravenous micafungin be reserved for selected patients with severe endophthalmitis in whom first-line therapy cannot be used because of drug resistance, and that in such cases systemic micafungin be combined with intravitreal antifungal therapy and vitrectomy—a clinical scenario closely paralleling our patient [19]. High-dose intravenous micafungin (200 mg daily) was therefore selected on the basis of its low MIC (0.125 μg/mL) relative to the markedly elevated MICs of all azoles and amphotericin B, with the increased dose intended to maximize ocular drug concentrations and combined with pars plana vitrectomy and intravitreal amphotericin B as adjunctive locally administered therapy. Intravitreal amphotericin B injections were employed as adjunctive therapy in an effort to exceed the MIC locally despite the organism's demonstrated relative resistance due to studies showing a wide range of susceptibility with regards to in vitro assay depending on the assay method [15]. The injections were performed at 1.5 week intervals due to the half-life of amphotericin B in vitrectomized eyes being significantly shorter [20]. This combined systemic-and-intravitreal approach is consistent with the strategy successfully employed by Aydin et al., who reported resolution of postoperative Scopulariopsis endophthalmitis using systemic and topical caspofungin in combination with voriconazole [11]. The role of intravitreal echinocandins in the management of fungal endophthalmitis remains poorly defined and is not currently endorsed by major treatment guidelines. Animal studies and isolated case reports have explored intravitreal caspofungin and micafungin, suggesting reasonable intraocular tolerability, safety and potential utility in cases involving multidrug-resistant molds; however, available data remain limited, dosing has not been standardized, and clinical experience in human endophthalmitis is sparse [[21], [22], [23]]. In our case, intravitreal micafungin was considered but ultimately not pursued given the absence of established intravitreal dosing guidelines. The ultimate need for enucleation despite aggressive medical and surgical therapy underscores the devastating nature of Scopulariopsis endophthalmitis. Several clinical reports have noted a lack of correlation between in vitro susceptibility results and clinical outcomes with Scopulariopsis, suggesting that factors beyond MIC values influence therapeutic success [6]. Furthermore, several clinical factors may have contributed to the suboptimal response to antifungal therapy in this patient. The patient's immunocompromised state due to ongoing cancer treatment also likely contributed to the poor response to therapy, as immunosuppression is a known risk factor for treatment failure in fungal infections [24,25]. Additionally, although rare, fungal infections may be directly or indirectly linked to the use of immunotherapy [26]. The presence of a dehisced scleral tunnel wound and subsequent scleral necrosis raises the possibility of scleral sequestration of the organism, in which fungal elements become protected within necrotic, poorly vascularized tissue and remain inaccessible to systemic and intravitreal antifungal therapy. Finally, while initial vitreous Gram stain demonstrated gram-positive cocci in addition to fungal elements, the bacterial component was felt to have been adequately treated by intravitreal vancomycin and ceftazidime administered at presentation and again at the time of vitrectomy, with subsequent intraocular and orbital cultures at enucleation showing no bacterial growth — making bacterial co-infection an unlikely contributor to the ultimate outcome. The primary limitation of this report is that the isolate was identified only to the genus level (Scopulariopsis sp.) by morphologic methods, as species-level confirmation by molecular techniques was not performed. Species-level identification could have provided additional information regarding species-specific susceptibility patterns and clinical associations within the genus, and we recommend that future cases incorporate molecular confirmation when feasible. Conclusion In summary, this case demonstrates the challenges in managing a rare type of fungal endophthalmitis, including the need for aggressive multimodal therapy with both systemic and intravitreal antifungals, despite which complete eradication may not be achievable. Enucleation may ultimately be curative. Early recognition, prompt antimicrobial susceptibility testing, and realistic prognostic counseling are essential components of management for these challenging infections. CRediT authorship contribution statement Sunny Qin: Writing – original draft, Investigation, Data curation. Rajiv E. Shah: Validation, Supervision, Conceptualization. Tal J. Rubinstein: Writing – review & editing, Resources. Preeti Parekh: Writing – review & editing, Visualization. Kristen S. Godwin: Writing – review & editing, Validation, Supervision, Project administration. Patient consent Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent form is available for review by the Editor-in-Chief. Authorship Authors attest that they meet the current ICMJE criteria for Authorship. Funding No funding or grant support Declaration of conflict of interest The authors declare no conflicts of interest related to this work. Acknowledgements None. References